The Lateral Flow Experts

Company name

ISCA Diagnostics

Project outline

Development of a Serodiagnostic Lateral-Flow Device Specific to Rhizopus arrhizus, the Principal Global Agent of Mucormycosis in Humans

Project objectives

  • Test detects target polysaccharide biomarker at low levels
  • Test can be read using Cube reader and Visual score card
  • Test results are available within 30 minutes and provided in a point of care setting
  • Test is specific for Rhizopus arrhizus

Project outcome of working with Lateral Dx

This is the first time that a quick and sensitive lateral-flow test for Mucormycosis has been reported, providing a point-of-care test for the disease.
Using purified EPS from human-pathogenic mucoralean fungi, the LFD was shown to be species-specific, detecting Rhizopus arrhizus (syn. R. oryzae) only
The sensitivity of the LFD was determined using EPS from R. arrhizus var. arrhizus (CBS112.07) diluted into the running buffer. Using both a score card and a Cube reader there were sequential and significant decreases in test (T) line intensities with increases in EPS concentrations between 0 μg EPS/mL (running buffer only) and 10 μg EPS/mL. Based on these results, the analytical limit of detection (LOD) was shown to be ~50 ng EPS/mL for the running buffer, using both scoring systems.

Statistics or data to compliment

We’re pleased to have partnered with Lateral Dx in the development of this novel diagnostic test for Mucormycosis. We are using the data to support commercialisation of the device as a near-patient test for this devastating disease. In addition, we have now partnered with Lateral Dx to develop a multiplex testing system for the disease.
Prof Christopher Thornton
ISCA Founder and Professor of Fungal Immunology

Newsletter Sign Up

Stay informed on the latest lateral flow test development and manufacture industry news, rapid antibody screening developments, our sample antibody conjugation projects and everything in between. Fill in the form below to start receiving our newsletter.